⌕
NovoCure · NVCR · Nasdaq
Tenet 38 · Weak
Compare
$11.14−1.42%At closeTenet 38 · Weak
$11.14−0.16 (−1.42%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD

NovoCure (NVCR) Income Statement

Is this a real, growing, cash-generative business, or a story propped up by accounting?

Sources Company filings FilingsHow we compute thisNot investment advice
Business engineChoppy: revenue compounds ~5.2%/yr (FY21→FY25), net margin −20.8%. Worth your attention in FY25: Share count (+7.8%). Visible in the receipts below.
The four lines that matter · FY21–FY25
Revenue ($M)▲8.3%
655.4
FY21→FY25CAGR +5.2%/yr
Net income ($M)▲19.2%
−136.2
one-off year: see footnoteCAGR —
Free cash flow ($M)▼9.3%
−75.7
FY21→FY25CAGR —
Diluted EPS▲21.8%
−1.22
FY21→FY25CAGR —
What the receipts whisper · what a headline number hides
Share count
+7.8%

103.4mn → 111.5mn diluted shares since FY21. Rising share count dilutes EPS. Growth must outrun it.

Capex
$26.6M

−37.8% YoY in FY25 · 4.1% of revenue.

What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($M)655.4Revenue−166.9COGS488.5Gross profit−224.5R&D−177.7SG&A−153.8Op income17.6Tax & other−136.2Net income

-21¢ of every revenue dollar becomes profit. The biggest cost lever is operating expenses.

Margin trend · direction beats level Gross Operating Net
806040200%sector median net margin ~3%FY21FY25

Over this window: gross 78.5% → 74.5%. Net margin -20.8% is below the sector median.

The receipt · income statement · FY21–FY25 USD thousands except per-share & ratios · hover a line for its definition
USD thousands except per-share & ratios
Line itemTTM †FY25FY24FY23FY22FY21YoYCAGR 21→25
Revenue & profitability
Revenue
725,388.0655,353.0605,220.0509,338.0537,840.0535,031.0▲8.3%+5.2%
Cost of revenue
166,721.0166,879.0137,181.0128,280.0114,867.0114,877.0▲21.6%+9.8%
Gross profit
558,667.0488,474.0468,039.0381,058.0422,973.0420,154.0▲4.4%+3.8%
Research & development
228,788.0224,544.0209,645.0223,062.0206,085.0201,303.0▲7.1%+2.8%
Selling, general & admin
212,427.0177,666.0189,827.0164,057.0132,753.0126,127.0▼6.4%+8.9%
Total operating expenses
683,213.0642,274.0638,535.0613,928.0512,496.0464,487.0▲0.6%+8.4%
Operating incomefeeds ROC rank
−124,546.0−153,800.0−170,496.0−232,870.0−89,523.0−44,333.0▲9.8%—
Other income, net
−5,998.017,550.039,334.041,130.07,677.0−7,742.0——
Pretax income
−130,544.0−136,250.0−131,162.0−191,740.0−81,846.0−52,075.0▼3.9%—
Income tax
−8,814.0−23.037,465.015,303.010,688.06,276.0——
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings
−121,730.0−136,227.0−168,627.0−207,043.0−92,534.0−58,351.0▲19.2%—
Per share
Diluted EPSbuyback-sensitive
−1.06−1.22−1.56−1.95−0.88−0.56▲21.8%—
Diluted shares (mn)
116.79111.47107.83106.39104.66103.43▲3.4%+1.9%
Margins
Gross margin70th pct in Healthcare
77.0%74.5%77.3%74.8%78.6%78.5%▼2.8pp−4.0pp
Operating margin
−17.2%−23.5%−28.2%−45.7%−16.6%−8.3%▲4.7pp−15.2pp
Net margin24th pct in Healthcare
−16.8%−20.8%−27.9%−40.6%−17.2%−10.9%▲7.1pp−9.9pp
† TTM = trailing four quarters through 2026-09-30.FY24 effective tax rate was −29% vs a −12% norm for this window, likely a one-time item; see the filing.FY25 effective tax rate was 0% vs a −12% norm for this window, likely a one-time item; see the filing.
FY13 – FY20 · 8 more years
Unlock the full history →
5 more years of statements and CSV export are on Premium, and 8 more on Ultimate.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
Annual report filed 2026-02-26 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.

What was NovoCure's revenue last fiscal year?

NovoCure reported revenue of $655.4M in fiscal 2025, up 8.3% from fiscal 2024.

What was NovoCure's net income?

NovoCure reported net income of −$136.2M in fiscal 2025, a net margin of −20.8%.

Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.